Medical Market Report

Global Antisense & Rnai Therapeutics Market By Type (Rna Interference, Sirna, Mirna, And Antisense Rna), By Application (Oncology, Cardiovascular, Renal, Neurodegenerative, Respiratory, Genetic, And Infectious Diseases), By Region And Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends And Forecast 2020-2029

  • 134905
  • 16-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    The report on Antisense & RNAi Therapeutics Market offers in-depth analysis on market trends, drivers, restraints, opportunities etc. Along with qualitative information, this report include the quantitative analysis of various segments in terms of market share, growth, opportunity analysis, market value, etc. for the forecast years. The global antisense & rnai therapeutics market is segmented on the basis of Type, Application, and geography. The worldwide market for Antisense & RNAi Therapeutics Market is expected to grow at a CAGR of roughly x.x% over the next ten years, and will reach US$ XX.X Mn in 2028, from US$ XX.X Mn in 2018, according to a new Market.us (Prudour Research) study.

    Antisense & RNAi Therapeutics Market Scope:

    By type, the market is segmented into RNA interference, SiRNA, MiRNA, and Antisense RNA. By Application, the market is divided into Oncology, Cardiovascular, Renal, Neurodegenerative, Respiratory, Genetic, and Infectious Diseases.
    Based on geography, market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include Glaxo Smith Kline, Sanofi Aventis / Genzyme, Isis Pharmaceuticals/ Ionis Pharmaceuticals, Arbutus Biopharma Ltd., Silence Therapeutics, Bio-Path Holdings Inc., Calando Pharmaceuticals, ICo Therapeutics, Quark Pharmaceuticals, Rexhan Pharmaceuticals, Biomarin/Prosensa, Regulus Therapeutics, Rxi Pharmaceuticals, Silenseed, Dicerna Pharmaceuticals, and Sirnaomics Inc..

    Key Market Segments

    Type

    RNA interference

    SiRNA

    MiRNA

    Antisense RNA

    Application

    Oncology

    Cardiovascular

    Renal

    Neurodegenerative

    Respiratory

    Genetic

    Infectious Diseases

    Key Market Players included in the report:

    Glaxo Smith Kline

    Sanofi Aventis / Genzyme

    Isis Pharmaceuticals/ Ionis Pharmaceuticals

    Arbutus Biopharma Ltd.

    Silence Therapeutics

    Bio-Path Holdings Inc.

    Calando Pharmaceuticals

    ICo Therapeutics

    Quark Pharmaceuticals

    Rexhan Pharmaceuticals

    Biomarin/Prosensa

    Regulus Therapeutics

    Rxi Pharmaceuticals

    Silenseed

    Dicerna Pharmaceuticals

    Sirnaomics Inc.

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis industry research (global industry trends) and Antisense & RNAi Therapeutics Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Antisense & RNAi Therapeutics Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Antisense & RNAi Therapeutics Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Antisense & RNAi Therapeutics Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Antisense & RNAi Therapeutics Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Antisense & RNAi Therapeutics Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Antisense & RNAi Therapeutics sub-markets, depending on key regions (various vital states).
    To analyze Antisense & RNAi Therapeutics Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Antisense & RNAi Therapeutics Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2012 to 2018, and also prediction to 2028.
    Primary worldwide Antisense & RNAi Therapeutics Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Antisense & RNAi Therapeutics Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players3. Global Antisense & RNAi Therapeutics Market Overview
    

    3.1. Antisense & RNAi Therapeutics Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges  3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Manufacturer Intensity Map4. Global Antisense & RNAi Therapeutics Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Antisense & RNAi Therapeutics Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. RNA interference
    

      4.4. SiRNA
    

      4.5. MiRNA
    

      4.6. Antisense RNA5. Global Antisense & RNAi Therapeutics Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Antisense & RNAi Therapeutics Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Oncology
    

      5.4. Cardiovascular
    

      5.5. Renal
    

      5.6. Neurodegenerative
    

      5.7. Respiratory
    

      5.8. Genetic
    

      5.9. Infectious Diseases6. Global Antisense & RNAi Therapeutics Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Antisense & RNAi Therapeutics Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Antisense & RNAi Therapeutics Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Antisense & RNAi Therapeutics Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia
    

      6.4. Latin America
    

        6.4.1. Latin America Antisense & RNAi Therapeutics Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Antisense & RNAi Therapeutics Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    
7. Global Antisense & RNAi Therapeutics Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. Glaxo Smith Kline
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments  7.4. Sanofi Aventis / Genzyme
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments  7.5. Isis Pharmaceuticals/ Ionis Pharmaceuticals
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments  7.6. Arbutus Biopharma Ltd.
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments  7.7. Silence Therapeutics
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments  7.8. Bio-Path Holdings Inc.
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments  7.9. Calando Pharmaceuticals
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments  7.10. ICo Therapeutics
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments  7.11. Quark Pharmaceuticals
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments  7.12. Rexhan Pharmaceuticals
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments  7.13. Biomarin/Prosensa
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments  7.14. Regulus Therapeutics
    

        7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments  7.15. Rxi Pharmaceuticals
    

        7.15.1. Company Overview
    
    7.15.2. Financial Highlights
    
    7.15.3. Product Portfolio
    
    7.15.4. SWOT Analysis
    
    7.15.5. Key Strategies and Developments  7.16. Silenseed
    

        7.16.1. Company Overview
    
    7.16.2. Financial Highlights
    
    7.16.3. Product Portfolio
    
    7.16.4. SWOT Analysis
    
    7.16.5. Key Strategies and Developments  7.17. Dicerna Pharmaceuticals
    

        7.17.1. Company Overview
    
    7.17.2. Financial Highlights
    
    7.17.3. Product Portfolio
    
    7.17.4. SWOT Analysis
    
    7.17.5. Key Strategies and Developments  7.18. Sirnaomics Inc.
    

        7.18.1. Company Overview
    
    7.18.2. Financial Highlights
    
    7.18.3. Product Portfolio
    
    7.18.4. SWOT Analysis
    
    7.18.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.